Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Kidney Cancer Gets A Double Uplift From Latest CHMP Meeting

Jul 25 2016

• By Alex Shimmings and John Davis

Thumbs Up

Related Content

Bristol Gets First Mover-Advantage, Again, With Opdivo Kidney Cancer Approval

Nov 23 2015

Exelixis’ Cabozantinib Cleared For Kidney Cancer, With Competitive Labeling

Apr 26 2016

Eisai Taps Novartis Oncology Firepower For Lenvima

Jun 03 2016

Value Measures, Side Effects Help Differentiate Drugs In Crowded Kidney Cancer Market

Jun 17 2016

Ipsen Pays Exelixis $200m Up Front For Ex-US Cometriq Rights

Mar 01 2016

Related Companies

Ipsen SA

Eisai Co., Ltd.

Novartis AG

Exelixis, Inc.

Pfizer Inc.

Bristol Myers Squibb Company

Roche Holding AG

Bayer AG

Takeda Pharmaceutical Co. Ltd.

Eli Lilly and Company

Merrimack Pharmaceuticals, Inc.

Additional Topics

Europe Approvals Market Intelligence Commercial Research & Development Cancer BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window